
        <!DOCTYPE html>
        <html>
        <head>
            <title>Donepezil PET Analysis Report</title>
            <style>
                body { font-family: Arial, sans-serif; margin: 20px; }
                h1, h2, h3 { color: #2c3e50; }
                .report-header { background-color: #f8f9fa; padding: 20px; border-radius: 5px; margin-bottom: 20px; }
                .section { margin-bottom: 30px; }
                .img-container { margin: 10px 0; text-align: center; }
                .img-container img { max-width: 100%; border: 1px solid #ddd; border-radius: 5px; }
                table { border-collapse: collapse; width: 100%; margin: 20px 0; }
                th, td { text-align: left; padding: 12px; border-bottom: 1px solid #ddd; }
                th { background-color: #f2f2f2; }
                tr:hover { background-color: #f5f5f5; }
                .positive-change { color: green; }
                .negative-change { color: red; }
            </style>
        </head>
        <body>
            <div class="report-header">
                <h1>Donepezil PET Analysis Report</h1>
                <h2>Condition: LPL</h2>
                <p>Date: 2025-03-06 01:23:50</p>
            </div>
            
            <div class="section">
                <h2>Summary of Findings</h2>
                <p>This report presents PET imaging analysis evaluating the effect of Donepezil in a subject with LPL condition.</p>
        
                <p><strong>Overall Drug Efficacy Score:</strong> 0.45</p>
            
                <h3>Pathway Effects:</h3>
                <ul>
                <li><strong>Amyloid:</strong> 0.00</li><li><strong>Tau:</strong> 0.28</li><li><strong>Apoptosis:</strong> 0.00</li><li><strong>Autophagy:</strong> 0.00</li><li><strong>Lipid:</strong> 0.00</li><li><strong>Synaptic:</strong> 0.00</li></ul>
                <table>
                    <tr>
                        <th>Biomarker</th>
                        <th>Mean Change</th>
                        <th>Interpretation</th>
                    </tr>
                    <tr>
                        <td>Amyloid PET SUVr</td>
                        <td class="positive-change">-31.7%</td>
                        <td>Reduction in amyloid burden</td>
                    </tr>
                    <tr>
                        <td>Tau PET SUVr</td>
                        <td class="positive-change">-18.1%</td>
                        <td>Reduction in tau pathology</td>
                    </tr>
                </table>
        
                <h3>Regional Changes</h3>
                <table>
                    <tr>
                        <th>Brain Region</th>
                        <th>Amyloid Change (%)</th>
                        <th>Tau Change (%)</th>
                    </tr>
        
                    <tr>
                        <td>Hippocampus</td>
                        <td class="positive-change">-41.2%</td>
                        <td class="positive-change">-23.6%</td>
                    </tr>
            
                    <tr>
                        <td>Entorhinal Cortex</td>
                        <td class="positive-change">-41.2%</td>
                        <td class="positive-change">-23.6%</td>
                    </tr>
            
                    <tr>
                        <td>Prefrontal Cortex</td>
                        <td class="positive-change">-34.9%</td>
                        <td class="positive-change">-19.9%</td>
                    </tr>
            
                    <tr>
                        <td>Temporal Lobe</td>
                        <td class="positive-change">-34.9%</td>
                        <td class="positive-change">-19.9%</td>
                    </tr>
            
                    <tr>
                        <td>Parietal Lobe</td>
                        <td class="positive-change">-28.5%</td>
                        <td class="positive-change">-16.3%</td>
                    </tr>
            
                    <tr>
                        <td>Posterior Cingulate</td>
                        <td class="positive-change">-28.5%</td>
                        <td class="positive-change">-16.3%</td>
                    </tr>
            
                    <tr>
                        <td>Precuneus</td>
                        <td class="positive-change">-28.5%</td>
                        <td class="positive-change">-16.3%</td>
                    </tr>
            
                </table>
            </div>
        
            <div class="section">
                <h2>Amyloid PET Analysis</h2>
        
                <h3>Amyloid PET Comparison</h3>
                <div class="img-container">
                    <img src="amyloid_comparison.png" alt="Amyloid PET Comparison">
                </div>
            
                <h3>Amyloid PET Difference Map</h3>
                <div class="img-container">
                    <img src="amyloid_difference_map.png" alt="Amyloid PET Difference Map">
                </div>
            
            </div>
        
            <div class="section">
                <h2>Tau PET Analysis</h2>
        
                <h3>Tau PET Comparison</h3>
                <div class="img-container">
                    <img src="tau_comparison.png" alt="Tau PET Comparison">
                </div>
            
                <h3>Tau PET Difference Map</h3>
                <div class="img-container">
                    <img src="tau_difference_map.png" alt="Tau PET Difference Map">
                </div>
            
            </div>
            
            <div class="section">
                <h2>Interpretation and Conclusion</h2>
        
                <p>Donepezil demonstrates moderate reduction in amyloid plaque burden, with notable effects in key memory-related regions.
                This suggests good target engagement and potential disease-modifying effects.</p>
                
                <p>The tau pathology shows modest improvement, which may represent early downstream effects or direct mechanism action.
                Continued treatment may yield further improvement in these biomarkers.</p>
            
                <p><strong>Clinical Significance:</strong> Reduction in amyloid and tau burden as measured by PET has been 
                associated with slower clinical progression in Alzheimer's disease. These imaging findings should be considered
                alongside clinical assessment of cognition and function.</p>
            </div>
        </body>
        </html>
        